Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
my mistake, read a string and just hit reply while I was laughing.
assigning technical indicators
To a stock with one fundamental flaw, they are in Chapter 11.
take your money and run.
I try to work buys nd sells to targets but rxii tricked me.
I am back into ISIS at 9 and watching for a 18 target to sell. They seem to have plenty of cash and were just beat down with a poorly written PR about a Phase II test.
Help Me, I am thinking about Buying
I keep reading all the positive feelings on the board and think I see a light.
Then I got the mail and read a letter that says Visteon is prohibited from making accellerated pension payments since they are underfunded in the pension plan.
Delisting Issue addressed?
I have not seen any info.
Hard to Trust these Guys.
Stock runs from 4 to 8 in a short time.
Only for the SOB's to issue new stock at 6 and cut the legs out.
What's next?
Thanks, I will look.
I start to be concerned when;
I see a nice move without news.
Just got burned by RXII who made a nice run from 4 to 8 in a short time, then decided to do a shelf registration at $6.00 yesterday.
Same thing happened with XOMA.
But it looks like these guys, ISIS have money in the bank so maybe this is a real move.
I would like to see it back near $18-20.
Looks like we are the only ones on IHUB that care.
Refer to My explaination in #4336
Show me why you still believe.
Some people believe it's dead
Visteon Common that is.
I don't understand the stock action for a company in Chapter 11.
I will wait for the case study in MBA Classes.
Good Luck with Your DD/b]
Read this for insight on the chapter 11
http://www.visteon.com/reorganization/supplier_faq_june1.pdf
Pay particular attention to #7, posted below;
7. Will suppliers and common carriers continue to be paid for goods and services
they provide to Visteon operations in the U.S.?
The company intends to pay suppliers and common carriers under agreed-upon trade
terms for goods provided or services rendered after the filing date. Any claims for goods
and services provided after the filing date are considered “administrative claims” and
receive priority status under bankruptcy law.
Suppliers that provided goods and services to Visteon prior to the filing date may have
what are referred to as “pre-petition claims.” Under Chapter 11, the law prohibits Visteon
from making any payments on account of unpaid debts for goods and services provided
to Visteon prior to the filing date without specific court approval. Any such pre-petition
claims will be addressed through the court-supervised reorganization process.
If you have a pre-petition claim, you must file a proof of claim with the U.S. Bankruptcy
Court for the District of Delaware, or be scheduled by the debtors as a creditor in these
cases, to receive payment on your claim. Proofs of claim forms are available on the Web
site of our claims agent at: www.kccllc.net/visteon. Our claims agent will provide
additional information on filing proofs of claim in the coming weeks. Visteon understands
the importance of timely payment and sincerely regrets the hardship or inconvenience
that this may cause you as a valued business partner.
Remember to do your own Due Dilligence.
Gilligan, Let me ask you, since you are the expert
Since declaring Chapter 11, what liabilities has Visteon paid during the past year?
My guess is only those to support the last year's production.
Did they stop payment on balance sheet liabilities?
As for continually posting, I am only responding to your concerns.
I am trying to help you.
Your Friend
Mr.10001
Good Luck on That
I am not a Bankruptcy specialist.
But I believe the purpose of a Chapter 11 is to permit a reorganization to allow the company to remain in business as a viable entity.
But as long as they pay into the pension plan I wish you well on holding the stock.
As for me I still want to short it.
One Other piece if information
For those holding stock in Visteon;
http://detnews.com/article/20100316/AUTO01/3160406/Visteon-will-keep-pension-plans
Visteon said the new plan "has the express and unanimous support" of a committee of lenders, and the backing of lenders who hold 74 percent of the company's debt.
Under the new plan, the lenders' $1.63 billion claim will be converted to stock in the new company, which would leave the reorganized company virtually free of debt in the United States.
The secured lenders will receive 85 percent of the stock in the new company once it emerges from bankruptcy. Unsecured lenders will get 9 percent of new stock, about 20 percent of the value of their claims, while trade lenders will get cash worth 50 percent of their claims. But Visteon's shareholders will be wiped out completely
Make sure you understand the RISK of holding on.......
I have followed the case.
I am a retiree of both companies, F & VC.
I wish you well, But If I could sell visteon stock at $0.75 I would.
They don't get a do over.
The securied creditors even us retirees are in line before shareholders.
But as I said, Good luck with your hopes.
There are better $0.75 stocks out there than VSTNQ.
What part of Bankruptcy Don't you Understand?
Common Stock shareholders always get nothing in a BK.
The CFO and CEO sold while there was still some thing to get.
It is incredible that the stock went back up. Just some crazy people the do not understand the process.
If you have any visteon common stock, sell it now or trade it later for GM stock, Kmart stock, chrysler stock, all of which are worthless now.
Scottrade won't let me short stocks less than $5.
Absolulely No Chance
The common is dog poop.
I only wish I could short it.
What are you smoking?
My Trade points are my decision when I buy.
They depend on my entry point.
Just to help you grow and learn;
I got in on 8/28 for 21 and again on 10/27 for 19.
double bottom with bad news.
So when I saw 27 after bouncing around 26 I was happy to lock in a profit.
I know you won't believe me but I don't care.
Next is not to look back if it breaks out but to be patient and wait for re-entry.
Your Friend
Mr.10001
Catalyst
The dropping of the Poison Pill could be a game changer.
My experience with IDCC is that 'Bad News' loss of a lawsuit, starting of a counter suit when they sue a possible patent infringer causes a precipitous drop in the share price.
On the other hand 'Good News' winning a suit, getting a new licensee or getting a payment only stop the drop and then there is a steady rise back to the 26-30 range.
I don't remember a time when there was an event that caused a spike up in the price.
So, looking at the past, I will be waiting to see IDCC act as in the past, and perhaps continue the run to the next plateau till some 'bad news' comes out drops it again.
As I said initially, "The dropping of the Poison Pill could be a game changer."
ps. Hello to BISON if he still watches.
Something has lit a fire under RXII
What is driving it?
I agree, Free exchange is how we all prosper
Speak your opinions freely...whether we agree or not...that is what this board is about...
Even Kings, should apply that rule.
Excuse Me McRoberts, I guess you are King of the Board
Paheka has been dethroned?
Some day you should explain your position that this stock will continue going up and that profit taking is wrong.
You sound like so many traders we've seen come and go`
Now you elevate yourself to a plurality "WE"
Please try not to judge anyone on these boards by what they post.
You really don't know anyone here. And everyone should keep their opinions and comments civil.
Otherwise return to the yahoo board.
As If I Care
Thank you for the vote of no confidence.
I don't make money on all trades, but when I am ahead 30% on a trade I will not lose.
Matt do you preview your posts before you publish?
They make you look like a bloody idiot.
Perhaps you should refrain from posting sentence fragments.
I agree, buy low sell higher
I still think this stock is closer to being a buy below 24 (nearer to under 22) than being a sell above 30.
But who am I to talk, I took profits at 27. I bought below 20.
I am greedy once I have a 30% + profit.
BUT the MM are conspiring to manipulate the price. I don't know how some of the posters can sleep at night.
R & R March 16, 2010 update/
We are raising our target price from $2 to $3 to reflect oncology pipeline progress and advancement, and increase in value of RXII investment:
CytRx reported 4Q09 and FY 2009 results today, and outlined its clinical trial plans for 2010. On this occasion, we are updating our model and raising our 12-month price target from $2/share to $3/share by using a comparables and sum-of-the parts valuation. The basis for the increase in the company’s value, in our view, comes from the progress made in 2009 and the increased visibility on the clinical development of CytRx’s oncology pipeline, which includes 5 Phase II trials this year, and the recent increase in the value of the company’s investment in RXi Pharmaceuticals (RXII Market Outperform), of which the company owns a 36% share.
2009 Earnings update: The company reported 4Q09 and FY 2009 results today, including a net loss for the quarter of $2.5M or $0.02) per share, compared to our and consensus estimate of ($0.04). Total operating expense for the quarter was $3.3M compared to $5.0M in the same quarter last year. R&D expense for the quarter was $1.1M, down 67% or $2.2M, from the $3.3M spent in 4Q08, while G&A expense for the quarter was $2.2M, compared to $1.8M in 4Q08. For FY 2009, the company reported a net loss of $4.8M or ($0.05) per share, compared to our net loss estimate of $7.5M or ($0.07) per share. CytRx ended 2009 with $32.6M in cash or ~$0.30/share.
A busy R&D year ahead, becoming a pure-play oncology company
with five phase II trials in in 2010. The company is preparing to start 5 Phase II trials in oncology with INNO-206, its doxorubicin prodrug, and Bafetinib, its Bcr-Abl and Lyn-kinase inhibitor. We remind investors that both compounds were acquired in June 2009, when CytRx was able to benefit from Innovive’s financial difficulties and acquire its compounds at bargain basement prices. The company is gearing up for an important
year, as it is completing its transformation from a neurology and RNAi company, to an oncology company following the spin-off of RXi
Pharmaceuticals (RXII) and the acquisition of Innovive Pharmaceuticals, both completed in 2008. The company is planning to eventually liquidate its position in RXII, followed by the potential spin out the molecular chaperone compounds.
Bringing oncology R&D know-how in-house. We believe CytRx’s shift
and focus on a single therapeutic area makes sense for the company, and we see it as a positive development, since we believe it will allow the company to build expertise in this area. We note that this focus in oncology is in accordance with the recent arrival of new Chief Medical Officer Dr. Daniel Levitt, who brings strong industry expertise from long
tenure in a number of biotech and pharmaceutical companies. Dr. Levitt joined CytRx in October 2009 from Cerimon Pharmaceuticals, where he was EVP, R&D and where he implemented three Phase III pivotal trials.
Prior roles include: global leader of oncology drug development at
Sandoz Pharmaceuticals (NVS Not Rated), Chief Operating Officer and Head of Research and Development at Affymax (AFFY Not Rated),
President and Head of R&D at Protein Design Labs, Chief Medical
Officer and Head of Clinical and Regulatory Affairs at Dynavax
Technologies Corporation (DVAX Not Rated), and Director, Clinical
Oncology and Immunology at Roche (RHHBY Not Rated).
(See page 2 for an overview of the CytRx clinical pipeline)
An overview of the current status of CytRx’s compounds:
1) INNO-206: clinical trials
The company will test INNO-206, its doxorubicin prodrug in 3 open-label Phase II trials in 2010:
1) pancreatic cancer (1H10)
2) gastric cancer (2H10)
3) soft tissue sarcoma (STS) (2H10)
INNO-206: Background info. The goal of the development of INNO-206 is to end up with an at least as effective and
less toxic version of doxorubicin, which is a widely-used drug in oncology, including breast, ovarian and lung cancer,
that unfortunately comes with significant safety issues, including cardiotoxicity. As we mentioned, INNO-206 is a
doxorubicin prodrug, and allows for the controlled and targeted release of doxorubicin to tumors. CytRx has worldwide
rights to INNO-206 through its acquisition of Innovive Pharmaceuticals in 2008. INNO-206 is a combination of
doxorubicin with an acid sensitive linker (EMCH). INNO-206 appears to act by a mechanism in which the EMCH binds
to albumin, allowing for transportation of the molecule. Circulating albumin (now with the accompanying INNO-206)
preferentially accumulates in tumors, where the acidic environment causes EMCH cleavage and the release of the
doxorubicin, and this way doxorubicin is effectively delivered at the tumor site.
INNO-206: Clinical Data. INNO-206 has previously completed Phase I testing, demonstrating its safety and
tolerability, and its optimal dosing has been evaluated. In the Phase I trial in solid tumors, out of 35 evaluable patients,
treatment with IV INNO-206 q3w resulted in 1 CR in small cell lung cancer; 3 PRs and 20 SDs. There was no acute
cardiotoxicity observed in this open-label trial of 41 patients, while the DLTs (mucositis and neutropenic fever)
occurred at 340 mg/m2 dose. A dose of 260 mg/m2 has been selected as the dose to be tested in Phase II trials.
2) Bafetinib: clinical trials
The company will test Bafetinib, its Bcr-Abl and Lyn-kinase inhibitorin2 open-label Phase II trials in 2010:
1) high rish B-cell chronic lymphocytic leukemia (B-CLL) (1H10)
2) Glioblastoma Multiforme (2H10)
3) Tamibarotene: clinical trials
CytRx will test its oral small molecule Tamibarotene in combination with chemotherapy or arsenic trioxide (ATO) as a
first-line treatment for acute promyelocytic leukemia (APL). In September 2009 the company initiated a dose escalation
trial with tamibarotene in combination with Cephalon’s (CEPH Not Rated) Trisenox (arsenic trioxide) in patients with
relapsed APL.
The drug has received both Orphan Drug Designation for APL and Fast Track Designation by the FDA for the
treatment of adult patients with relapsed or refractory APL following treatment with all-trans retinoic acid (ATRA) and
arsenic trioxide, and orphan medicinal product status by the EMA for APL. We remind investors that the company has
NA and EU rights for Tamibarotene.
The STAR-1 trial: This is an open-label, non-randomized trial, where patients were administered 6 mg of oral
tamibarotene daily until they achieved remission or for a maximum of 56 days. Following remission, patients have the
option to continue treatment with tamibarotene at the same dose for three 4-week cycles on 8-week intervals. The
primary endpoint of the trial is rate of durable CR for tamibarotene therapy when administered as a single agent to
adult patients following treatment failure with ATRA and arsenic trioxide.
The CytRx/Cephalon trial with tamibarotene: In addition to the registration STAR-1 trial, CytRx is currently
conducting a dose escalation study of tamibarotene in combination with Cephalon’s (CEPH Not Rated), Trisenox
(arsenic trioxide) in patients with relapsed acute promyelocytic leukemia (APL). CytRx and Cephalon are paying for
this study, whose objectives are to examine whether the combination of the two drugs is safe and a possible read on
the combination’s efficacy, and to determine the appropriate doses for future trials testing the tamibarotene/Trisenox
combination as a first-line treatment for patients not wanting exposure to anthracyclines. This is a multi-center Phase I
dose escalation trial that will enroll between 16 and 22 patients with relapsed in three dose groups. The patients will be
treated with either two or three six-week cycles of IV arsenic trioxide and self-administered oral tamibarotene tablets
with 2-6 weeks between cycles. A total of 10 patients will be enrolled at the MTD, for one or two additional cycles of
therapy, and the dose for the subsequent Phase II trial will be the dose at which at least 50-60% of the patients
tolerate the treatment or the maximum dose used in this trial.
Rationale behind the CytRx/Cephalon trial: There are currently no approved 3rd-line treatment options for refractory
APL subjects. CytRx has recently been granted European Orphan Drug status for tamibarotene in that setting.
Currently, front-line APL patients are treated with all-trans retinoic acid (ATRA) plus anthracycline-based
chemotherapy, typically followed by maintenance with ATRA with or without low-dose chemotherapy. The ultimate goal
of the current study would be that the tamibarotene and arsenic trioxide combo would result in a similar CR rate as the
ATRA/arsenic trioxide combination, but with less toxicity and a lower relapse rate, and could expand Tamibarotene’s
intended use from 3rd-line to the larger front-line setting.
4) Arimoclomol: The FDA recently lifted the clinical hold it had placed on the Phase II trial of Arimoclomol in January
2008. The company is currently seeking a partner for the compound and is also considering a “spin-out transaction” of
the molecular chaperone assets.
Details on the new clinical trial protocol: The new protocol is for a placebo-controlled, double-blind ascending dose
study evaluating Arimoclomol as a treatment for ALS. The study will test progressive groups of patients, each with
between 20 and 30 ALS patients over the period of 3 months. 15 patients will receive Arimoclomol at various dose
levels in combination with a fixed dose of 50mg twice daily of riluzole, while 5 to 15 patients will receive placebo and
riluzole at the same fixed dose. The first group will receive Arimoclomol 100 mg capsules three times daily (tid). Every
four weeks, an additional group of ALS patients will begin three-month testing with 6 patients receiving Arimoclomol tid
dosing at a 75 mg per dose increase from the prior group. The maximum dose in the protocol allows for testing
Arimoclomol at 400 mg three times daily.
Efficacy endpoints: In addition to testing the drug’s safety, the trial will include two widely accepted measures of
efficacy: 1) ALSFRS-R, a composite endpoint which measures a patient’s overall functional capacity, and 2) Vital
Capacity (VC), an assessment of a patient’s lung capacity. An independent safety monitoring board will review results
prior to initiating each consecutive increase in dose level. We expect that once it is initiated, the trial will take about
nine months to enroll and to have data on the primary endpoint within 18 months of initiation of enrollment.
Background on the clinical hold: We remind investors that the Phase IIb trial was placed on clinical hold in January
2008, just four weeks after the trial had been initiated, and before any patients had been dosed in the 390-patient trial.
The agency had requested additional preclinical studies to be performed before deciding on removal of the clinical
hold. According to the company, the agency’s decision to place the trial in clinical hold was not based on any data that
had been generated on human clinical trials, but rather on the agency's desire to look at some additional data from
animal toxicology studies, which the company has now completed and provided to the FDA.
We are reiterating our Market Outperform Rating and raising our 12-month price target to $3/share. We reach
our 12-month price target using a comparables and sum-of-the-parts analysis. We used comparable companies in the
small cap oncology space, added value for the company’s 36% stake in RXi Pharmaceuticals (RXII Market
Outperform), and the company’s cash position 12 months from now.
Thanks, Just what I was looking for.
Good to see it is on the key document list.
As for the attack dogs
Illegitimi non carborundum
Upgrade
Rodman & Renshaw Raises CytRx Target Price to $3.00
I have just received an 8 pg pdf.
As soon as I find a link I will post it.
paheka-- kING OF THE BOARD
Small minds, quickly go into attack mode.
Now I get your posts.
You don't know how to play nice.
so please answer me only when I ask You a question.
Thank You for the answer
I will be surprised if any congress person responds.
They appear to me to have very short attention spans and even shorter reading comprehension.
The letter I read is very difficult to follow because there does not seem to be a specific ation the petioner is asking for.
So maybe XDX will identify what he wants congress to do.
Thanks for responding without attacking me...............
No, re-entry point still as stated before
Thanks for worring about my money. But I got in ISIS at $8.88
As for IDCC I am just interested in learning what is the point of the report.
Unfortunately, some board members take my questions as bashing.
I am just asking a question.
Do you know the answer?
What is the expected OMB action?
It is not stated in the stuff I have read from XDX
SOMEONE did a lot of work,
Where is the statement of what they are asking for?
Who Elected pa he ka king of this Board?
Trust me I don't want to take over your board.
Just a simple question.
Perhaps you can answer it? I asked:
"where is the original filing"
Who is it going to?
What is the expected outcome.
Someond did a lot of work, what are they asking the OMB, Office of Management and Budget, to do?
Doesn't seem like an attempt to disrupt and Hi Jack your board.
What remedy are you seeking from OMB?
Perhaps it was in the original complaint?
Where is the original complaint?
Lots of data though.
The purpose of this report is what?
XDX
The large volume of postings regarding this report means it is being constructed for some purpose.
I fail to understand;
What will be done with it?
Who is it going to be sent to?
What is the expected outcome?
Please clarify.
Thanks
Upbeat article from Yahoo Board
Make me want to Buy More
http://www.bloggingstocks.com/2010/03/12/biotech-expert-eyes-isis-pharmaceuticals-isis/
The reason for your optimism?
$1.00 why?
Though I would like to see it happen.
I have no special information
The past history of the company is my guide.
It is an unloved stock followed by a handful of botique investment houses. They make an effort to stay current on it and buy low and sell higher.
I was introduced to it a long time ago, 10 years + and have traded in and out on news that spooked the market for the stock.
ie; nokia wins suit, big sell off, buy in when it hits 20. It slowly wanders up to 26-27 sell, invest somewhere else and wait for the inevitable negative news that will drop it again.
Look at a 5-10 year chart of this company.
I tried to mention this before and was attacked by the board bulls.
I sold idcc and bought isis and made 10% today.
I will hold it till idcc presents a better opportunity.
Good luck.
March 3 was my buy date
I only wish I was more sure then.
I had to get my basis down to a manageable level. Another day like today and I am in the GREEN.